QUINN SCHULTE: Open Payments
NPI 1982975652 · COUNCIL BLUFFS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,250 in 45 payments from 17 companies in 2025. Trend: 2023 $1,280 · 2024 $640 · 2025 $1,250
Food & beverage: $1,250
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $304 |
| Amgen Inc. | 10 | $206 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| SANOFI-AVENTIS U.S. LLC | 1 | $122 |
| Sumitomo Pharma America, Inc. | 3 | $77 |
| Novartis Pharmaceuticals Corporation | 4 | $72 |
| ABBVIE INC. | 3 | $60 |
| Gilead Sciences, Inc. | 2 | $59 |
| Esperion Therapeutics, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $36 |
Products named: Repatha, Auvelity, TZIELD, BREZTRI, AIRSUPRA, GEMTESA, LEQVIO, EVENITY.
Industry payments across IA — which companies pay providers there.
